Colorectal Carcinoma, Cyclooxygenases, and COX Inhibitors

Area of Science:

• Gastroenterology
• Oncology
• Pharmacology

Background:

• Colorectal carcinoma (CRC) is a prevalent gastrointestinal cancer, often sporadic, with concerning rising incidence and shifting demographics.
• Malignant transformation in CRC is a slow process originating from benign polyps, with adenomatous polyps showing significant cyclooxygenase (COX) upregulation, especially COX-2.
• COX enzymes drive prostaglandin synthesis, promoting inflammation and cell proliferation, key factors in colorectal carcinogenesis.

Purpose of the Study:

• To review and highlight the overexpression of COX enzymes in adenomatous polyps.
• To provide evidence supporting the role of COX inhibition by NSAIDs in preventing colorectal cancer.
• To discuss specific NSAIDs and their effects on polyp progression.

Main Methods:

• Literature review collating evidence on COX enzyme expression in adenomatous polyps.
• Analysis of studies investigating the effects of NSAIDs on colorectal polyp progression.
• Examination of experimental data on COX inhibitors in CRC prevention.

Main Results:

• Adenomatous polyps exhibit marked upregulation of cyclooxygenases (COX), with a significant emphasis on the COX-2 isoform.
• Non-steroidal anti-inflammatory drugs (NSAIDs) targeting COX-1 and COX-2 have been investigated for CRC prevention.
• Aspirin and Sulindac demonstrated efficacy in halting polyp progression and inducing regression; Celecoxib also showed potential.

Conclusions:

• Overexpression of COX enzymes in adenomatous polyps supports the rationale for COX inhibition in CRC prevention.
• NSAIDs, including aspirin, sulindac, and selective COX-2 inhibitors like celecoxib, show potential in preventing and managing colorectal polyps.
• Targeting COX pathways with NSAIDs represents a viable strategy for colorectal cancer chemoprevention in high-risk individuals.